Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Debt to Equity (2016 - 2022)

Aptevo Therapeutics' Debt to Equity history spans 8 years, with the latest figure at $0.19 for Q4 2022.

  • For Q4 2022, Debt to Equity fell 98.48% year-over-year to $0.19; the TTM value through Dec 2022 reached $0.19, down 98.48%, while the annual FY2022 figure was $0.19, 98.48% down from the prior year.
  • Debt to Equity for Q4 2022 was $0.19 at Aptevo Therapeutics, down from $0.25 in the prior quarter.
  • Across five years, Debt to Equity topped out at $12.64 in Q4 2021 and bottomed at -$0.82 in Q1 2022.
  • The 5-year median for Debt to Equity is $0.69 (2019), against an average of $1.98.
  • The largest annual shift saw Debt to Equity surged 1046.58% in 2020 before it tumbled 158.02% in 2022.
  • A 5-year view of Debt to Equity shows it stood at $0.63 in 2018, then skyrocketed by 164.56% to $1.68 in 2019, then dropped by 9.99% to $1.51 in 2020, then soared by 737.39% to $12.64 in 2021, then plummeted by 98.48% to $0.19 in 2022.
  • Per Business Quant, the three most recent readings for APVO's Debt to Equity are $0.19 (Q4 2022), $0.25 (Q3 2022), and $0.19 (Q2 2022).